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Previewscounterintuitive. Nevertheless, they are
consistent with recent data showing that
running distance is inversely correlated
with evoked dopamine release in NAc in
rats (Tarr et al., 2004) and that hyperloco-
motion can occur independent of dopa-
mine transmission in NAc (Chartoff et al.,
2005). How does ablation of STAT3
signaling in VTA dopamine neurons,
concomitant with reductions in evoked
dopamine release in NAc, precipitate
such dramatic increases in the rewarding
properties of running? The authors
offered a tantalizing piece of preliminary
evidence suggesting that the STAT3DAT
KO mice have reduced pre-prodynorphin
mRNA levels in the VTA. Pre-prodynor-
phin is produced by the so called ‘‘direct
pathway’’ medium spiny neurons in stria-
tum, which provide feedback innervation
to the midbrain dopamine system. More-
over, it is known that dynorphin, the
mature opioid peptide encoded by this
precursor gene, stimulates k opioid re-
ceptors (KORs) to inhibit locomotor activ-
ity. Perhaps reductions in KOR signaling
in the VTA, driven by decreases in dopa-mine release in NAc, stimulates running
behavior in a dopamine-independent
manner in the STAT3DAT KO mice?
In summary, the present data provide
important new insights into how leptin,
and other signaling molecules acting
through STAT3 in VTA dopamine neurons,
can influence physical activity. Endurance
training, such as distance running, often
induces feelings of well-being and happi-
ness, commonly referred to as ‘‘runner’s
high.’’ It will be interesting to determine if
reductions in STAT3 signaling in VTA
dopamine neurons explains this effect. If
so, perhaps inhibitors of STAT3 signaling
in VTA will increase willingness to exer-
cise, and increase energy expenditure, in
overweight individuals. However, it is not
too fanciful to speculate that such inhibi-
tors could boost endurance of distance
runners, offering an unfair advance in
competitive settings. The findings may
also be relevant to anorexia nervosa, a
condition associated with low circulating
levels of leptin and in which sufferers are
often hyperactive and prone to over-
exercising.Cell Metabolism 2REFERENCES
Bates, S.H., Stearns, W.H., Dundon, T.A., Schu-
bert, M., Tso, A.W., Wang, Y., Banks, A.S., Lavery,
H.J., Haq, A.K., Maratos-Flier, E., et al. (2003).
Nature 421, 856–859.
Carr, K.D. (1996). Neurochem. Res. 21, 1455–
1467.
Chartoff, E.H., Heusner, C.L., and Palmiter, R.D.
(2005). Neuropsychopharmacology 30, 1324–
1333.
Fernandes, M.F.A., Matthys, D., Hryhorczuk, C.,
Sharma, S., Mogra, S., Alquier, T., and Fulton, S.
(2015). Cell Metab. 22, this issue, 741–749.
Fulton, S., Woodside, B., and Shizgal, P. (2000).
Science 287, 125–128.
Leinninger, G.M., Jo, Y.H., Leshan, R.L., Louis,
G.W., Yang, H., Barrera, J.G., Wilson, H., Opland,
D.M., Faouzi, M.A., Gong, Y., et al. (2009). Cell
Metab. 10, 89–98.
Roberts, M.D., Gilpin, L., Parker, K.E., Childs, T.E.,
Will, M.J., and Booth, F.W. (2012). Physiol. Behav.
105, 661–668.
Tarr, B.A., Kellaway, L.A., St Clair Gibson, A., and
Russell, V.A. (2004). Behav. Brain Res. 154,
493–499.
Verhagen, L.A., Luijendijk, M.C., and Adan, R.A.
(2011). Eur. Neuropsychopharmacol. 21, 274–281.Beyond Hit-and-Run:
Stem Cells Leave a Lasting MemoryKelvin S. Ng,1,2,3 Thomas M. Kuncewicz,1,2,3 and Jeffrey M. Karp1,2,3,*
1Harvard-MIT Division of Health Sciences and Technology, Cambridge, MA 02139, USA
2Department of Medicine, Division of Biomedical Engineering, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115,
USA
3Harvard Stem Cell Institute, Cambridge, MA 02138, USA
*Correspondence: bwhkarp@gmail.com
http://dx.doi.org/10.1016/j.cmet.2015.09.019
While mesenchymal stem cells (MSCs) are rapidly cleared from the body following systemic transplantation,
their therapeutic benefits typically persist. In this issue, Liu et al. (2015) reveal that the ability of transplanted
MSCs to alleviate osteoporosis in systemic lupus erythematosus is maintained through epigenetic changes
conferred by secretory action of the MSCs.The promise of cell therapy in replacing or
regenerating damaged tissues and re-
turning tissue to homeostasis has ush-
ered in hundreds of clinical trials including
>500 that employ mesenchymal stem
cells (MSCs). MSCs differentiate into
osteogenic, chondrogenic, and adipo-genic lineages and are also appreciated
for their immunomodulatory properties
and ability to evade host immune attack
(Ankrum et al., 2014). Despite their im-
mune-evasiveness, transplanted MSCs
fail to persist in vivo and are thought to
impart therapeutic benefits via a ‘‘hit-and-run’’ mechanism (von Bahr et al.,
2012). Interestingly, these benefits remain
detectable long after the transplanted
MSCs disappear (Gnecchi et al., 2008;
Ranganath et al., 2012; von Bahr et al.,
2012). Multiple studies have demon-
strated that MSC-conditioned media2, October 6, 2015 ª2015 Elsevier Inc. 541
Figure 1. Wild-Type MSCs Restore the Ability of Faslpr MSCs to Form Bone by Inducing
Epigenetic Changes
(A)MSCswith Faslprmutation are globally hypomethylated. Hypomethylation of theNotch1 gene promoter
impairs osteogenic differentiation. Transplantation of wild-type MSCs provides functional wild-type Fas
through EVs and reverses effects due to the Faslprmutation, eliciting downstream epigenetic changes that
restore osteogenic capacity.
(B) Specifically, Fas promotes the release of miR-29b into the extracellular compartment without affecting
pri-miR-29b levels. The overall downregulation of intracellular miR-29b upregulates Dnmt1, which
reverses hypomethylation of the Notch1 gene promoter, thereby promoting osteogenic differentiation.
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MSCs themselves, and the ‘‘paracrine hy-
pothesis’’ was proposed to support the
‘‘hit-and-run’’ mechanism (Gnecchi
et al., 2008; von Bahr et al., 2012).
Secreted cytokines (Ranganath et al.,
2012) and extracellular vesicles (EVs)
such as exosomes (Rani et al., 2015)
have been strongly implicated as media-
tors of MSC action. However, deciphering
how these secretory factors elicit and
maintain therapeutic benefits in vivo re-
mains a complex task. A single MSC at a
given time and location in vivo releases a
plethora of cytokines and vesicles, each
likely having a distinct fate in the extracel-542 Cell Metabolism 22, October 6, 2015 ª20lular milieu. In a typical MSC transplant, a
large number of MSCs (from tens of thou-
sands of cells in mice to hundreds of mil-
lions of cells in humans) are systemically
administered and distributed across the
body. Without the ability to accurately
map the MSC secretome and its fate,
target cell types and mechanisms of ther-
apeutic benefit are difficult to predict. A
bottom-up approach of elucidating the
composition and fate of the secretome
may therefore be limited.
In this issue, Liu et al. (2015) report a
top-down approach instead. By repeat-
edly comparing specific cell types in
recipient mice before and after MSC15 Elsevier Inc.transplantation, the authors systemati-
cally interrogated molecular changes in
the recipient and linked them to the secre-
tome of transplanted MSCs. After
observing that wild-type MSCs can alle-
viate osteoporosis and promote bone for-
mation in Faslpr lupus mice, the authors
hypothesized and discovered that wild-
type MSCs restore the ability of Faslpr
MSCs to form bone by inducing epige-
netic changes (Figure 1). In Faslpr MSCs,
the mutation Faslpr is associated with a
global hypomethylation profile—particu-
larly of Notch genes—which is in turn
associatedwith downregulation of at least
three DNA methyltransferases: Dnmt1,
Dnmt3a, and Dnmt3b. Dnmt1, but not
Dnmt3a and Dnmt3b, was found to
impact osteogenic differentiation of
MSCs. Again by comparing Faslpr MSCs
before and after transplantation of wild-
type MSCs, the authors uncovered that
the Faslpr mutation upregulates miR-29b
and inhibits Dnmt1 expression, although
pri-miR-29b levels remain unaltered.
In vitro, miR-29b can be detected intra-
cellularly and extracellularly. Simulating
the Faslpr mutation by siRNA knockdown
of Fas in wild-type MSCs increased the
ratio of intracellular to extracellular miR-
29b without perturbing pri-miR-29b
levels. This strongly indicates that MSC
transplantation rectifies epigenetic de-
fects due to the Faslpr mutation to restore
osteogenesis and alleviate osteoporosis.
Fas is a cell surface receptor tradition-
ally known to trigger apoptosis, but it
has recently been found to regulate
migration, inflammation, and proliferation
(Brint et al., 2013). The study by Liu et al.
(2015) not only broadens the repertoire
of Fas functions but also demonstrates
that MSC transplantation can restore
functions lost because of the Faslpr muta-
tion. Strikingly, the authors show that exo-
somes from wild-type MSCs carry and
transfer functional, wild-type Fas to Faslpr
MSCs, arming the FaslprMSCs with exog-
enous Fas to restore their capacity for
osteogenic differentiation (Figure 1).
Unlike cytokines and other secretory
factors, EVs such as exosomes are intri-
cate assemblies of lipids, proteins, and
nucleic acids. By fusing with cell mem-
branes, EVs can transfer membrane and
cytosolic content to supplement functions
that the recipient cell would otherwise
lack (EL Andaloussi et al., 2013). This is
consistent with the transfer of Fas protein
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Previewssuggested by Liu et al. (2015). Potentially,
wild-type MSC-EVs could also transfer
mRNA, miRNA, cytosolic proteins, and
other membrane proteins to elicit and/or
potentiate the observed epigenetic
changes. Previous work by others
showed that MSC-EVs can upregulate
expression of a growth factor receptor in
recipient cells by transferring mRNA en-
coding the receptor (Tomasoni et al.,
2013). Whether transfer of Fas mRNA
could be an alternative mechanism to
supplement Fas function remains to be
determined.
Meanwhile, although Liu et al. (2015)
did not investigate if secretory factors
other than EVs could supplement Fas
function, it is difficult to imagine how cyto-
kines and small molecules can upregulate
Fas in cells that lack a functional Fas
gene. A complex interplay of signaling
factors is typically necessary to elicit
epigenetic changes (Mohammad and
Baylin, 2010). The ability of a secretome
to induce epigenetic changes across
Faslpr MSCs at different sites in the bone
marrow implies a more sophisticated ma-
chinery (perhaps EVs) that co-delivers
multiple signals per interaction with a
cell. Indeed, EV-mediated effects can be
so potent that in many studies, including
Liu et al. (2015), MSC-EVs alone canreproduce the therapeutic benefits of
MSCs (Rani et al., 2015). Like MSCs,
MSC-EVs have been shown to alleviate
damage in organs including the heart,
lungs, kidneys, and liver and in systemic
diseases such as graft-versus-host dis-
ease (Rani et al., 2015). Because EVs
co-deliver multiple signals, delineating
the mechanisms of action of MSC-EVs is
not straightforward. Moreover, while
MSC-EVs can directly interact with tis-
sue-specific cells as Liu et al. (2015)
demonstrate, indirect interactions should
not be overlooked. Mounting evidence in-
dicates that immune cells communicate
with each other by disseminating anti-
gen-specific information via EVs (EL An-
daloussi et al., 2013). Likewise, MSC-
EVs may interact with intermediary cells
that in turn release signals that may
include EVs to damaged tissues, launch-
ing a complex signaling network similar
to endocrine pathways. Wild-type MSC-
EVs may therefore effect epigenetic
changes in many more cell types besides
Faslpr MSCs, which could explain the
reversal of tissue damage in multiple or-
gans as observed by Liu et al. (2015).
The ability of a stem cell therapy or its
secretory products to erase pathological
‘‘memory’’ and coax diseased cells to
adopt a healthy phenotype providesCell Metabolism 2hope for regenerative medicine or even
rejuvenation. Whether such a mechanism
can be harnessed to achieve long-term
therapeutic effects, however, is worthy
of further investigation.
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Tumors are metabolically heterogeneous, and subpopulations of tumorigenic cells have been recently
described to rely more on mitochondrial respiration than glycolysis for energy production. In this issue,
Sancho et al. (2015) demonstrate that MYC is amaster switch regulatingmetabolic programs in different sub-
populations of pancreatic tumor cells.When metazoans evolved, cells lost the
ability to proliferate in response to the
availability of nutrients in the microenvi-ronment, a behavior that persists in all
single-cell beings frombacteria to eukary-
otic microorganism. The loss of nutrient-regulated proliferation is an essential
adaptation for multicellular organisms
to maintain spatial control of complex2, October 6, 2015 ª2015 Elsevier Inc. 543
